Economic value and cost-effectiveness of biventricular versus right ventricular pacing: results from the BLOCK-HF study

References

• Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492.
   PubMed Web of Science ®Google Scholar
• Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013;34:2281–2329.
   PubMed Web of Science ®Google Scholar
• Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) trial. JAMA. 2002;288:3115–3123.
   PubMed Web of Science ®Google Scholar
• Lamas GA, Lee KL, Sweeney MO, et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med. 2002;346:1854–1862.
   PubMed Web of Science ®Google Scholar
• Curtis AB. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;369:579.
   PubMedGoogle Scholar
• Curtis AB, Adamson PB, Chung E, et al. Biventricular versus right ventricular pacing in patients with AV block (BLOCK HF): clinical study design and rationale. J Cardiovasc Electrophysiol. 2007;18:965–971.
   PubMed Web of Science ®Google Scholar
• Linde C, Mealing S, Hawkins N, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction). Eur Heart J. 2011;32:1631–1639.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE): guide to the methods of technology appraisal; 2013 [cited 2015 May 11]. Available from: https://www.nice.org.uk/guidance/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781.
   Google Scholar
• Khazanie P, Liang L, Qualls LG, et al. Outcomes of medicare beneficiaries with heart failure and atrial fibrillation. JACC Heart Fail. 2014;2:41–48.
   PubMed Web of Science ®Google Scholar
• Academy of Managed Care Pharmacy (AMCP): a format for submission of clinical and economic evidence in supprt of formulary consideration. The AMCP format for formulary Submissions: Version 4.0; 2016 April [cited 2019 March 8]. Available from: https://www.amcp.org/FormatV4.
   Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices–overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Making. 2012;32:667–677.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE): technology appraisal number TA314. Final appraisal determination (FAD); 2014 [cited 2015 May 11]. Available from: https://www.nice.org.uk/guidance/ta314.
   Google Scholar
• Feldman AM, de Lissovoy G, Bristow MR, et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005;46:2311–2321.
   PubMed Web of Science ®Google Scholar
• Noyes K, Veazie P, Hall WJ, et al. Cost-effectiveness of cardiac resynchronization therapy in the MADIT-CRT trial. J Cardiovasc Electrophysiol. 2013;24:66–74.
   PubMed Web of Science ®Google Scholar
• Wells GA, Douglas C, Nichol G, et al. Cost-effectiveness of cardiac resynchronization therapy (CRT-D) for mild to moderate heart failure. Heart Rhythm Society Congress; 2012 [cited 2015 May 11]. Available from: http://ondemand.hrsonline.org/media/HRS2012AM_4/AB32/7766/7766.pdf.
   Google Scholar
• van Gelder BM, Meijer A, Bracke FA. The optimized V-V interval determined by interventricular conduction times versus invasive measurement by LVdP/dtMAX. J Cardiovasc Electrophysiol. 2008;19:939–944.
   PubMed Web of Science ®Google Scholar
• Gohler A, Geisler BP, Manne JM, et al. Utility estimates for decision-analytic modeling in chronic heart failure–health states based on New York Heart Association classes and number of rehospitalizations. Value Health. 2009;12:185–187.
   PubMed Web of Science ®Google Scholar
• Fryback DG, Dunham NC, Palta M, et al. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care. 2007;45:1162–1170.
   PubMed Web of Science ®Google Scholar
• Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1172–1177.
   PubMed Web of Science ®Google Scholar
• Khazanie P, Hammill BG, Qualls LG, et al. Clinical effectiveness of cardiac resynchronization therapy vs medical therapy alone among patients with heart failure: an analysis of the ICD and ADHERE national registries. Circ Heart Fail. 2014;7:926–934.
   PubMed Web of Science ®Google Scholar
• Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace. 2015;17:767–777.
   PubMed Web of Science ®Google Scholar
• Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail. 2001;7:176–182.
   PubMed Web of Science ®Google Scholar
• Calvert MJ, Freemantle N, Yao G, investigators C-H, et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J. 2005;26:2681–2688.
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321.
   PubMed Web of Science ®Google Scholar